Trial Profile
Open label, phase III, multicentric randomised trial, comparing five years of treatment with a non steroidal aromatase inhibitor, either anastrozole or letrozole, versus switching after 2-3 years to the steroidal aromatase inhibitor exemestane in early stage breast cancer patients.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Nov 2012
Price :
$35
*
At a glance
- Drugs Anastrozole (Primary) ; Letrozole (Primary) ; Exemestane
- Indications Breast cancer
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms DOUBLE
- 08 Jun 2011 New trial record